Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...

BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...

The healthcare and fitness wearables landscape is transforming rapidly, with tech giants investing heavily to improve the ...

Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan ...

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B, with 26 significant positions making up the majority of the portfolio. The top five holdings—Incyte, BeiGene, ACADIA Pharma ...

Knight Therapeutics Inc. GUD-T has signed a deal to buy the assets of Paladin Pharma Inc. as the Canadian drug company looks to build out its domestic business after a strategic push into South ...